Related Experiment Videos
Palivizumab: an overview
1Neonatal Unit, St George's Hospital, London.
Hospital Medicine (London, England : 1998)
|March 9, 2000
Abstract:
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if given prophylactically throughout the RSV season.